

Freedom of Information Act 2000 – Request Reference FoI/24/011
Immunomodulatory Medications

How many patients has your trust/health board treated in the past 6 months (for any disease) with the following drugs:

For the period 1 July 2023 to 31 December 2023:

- Aubagio (~~teriflunomide~~) – 4, unable to be brand-specific with this drug (figure includes all brands).
- Avonex (interferon beta-1a) – 0
- Betaferon (interferon beta-1b) – 0
- Brabio (glatiramer acetate) – 3
- Copaxone (glatiramer acetate) – 0
- Extavia (beta interferon-1b) – 0
- Gilenya (~~fingolimod~~) – 40, unable to be brand-specific with this drug (figure includes all brands).
- Lemtrada (alemtuzumab) – 10
- Kesimpta (ofatumumab) 20
- Mavenclad (cladribine) – 11
- Mayzent (siponimod) – 33
- Ocrevus (ocrelizumab) – 130
- Plegridy (peginterferon beta-1a) – 2
- Ponvory (ponesimod) – 3
- Rebif (beta interferon-1a) – 0
- Tecfidera (dimethyl fumarate) – 111
- Tysabri (natalizumab) – 89
- Tysabri (natalizumab) pre-filled syringes ONLY – 70
- Vumerity (diroximel fumarate) – 8
- Zeposia (ozanimod) – 3